Bystolic: Precise Blood Pressure Control and Cardiovascular Protection
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.40 | $42.14 (0%) | 🛒 Add to cart |
| 60 | $1.09 | $84.28 $65.36 (22%) | 🛒 Add to cart |
| 90 | $0.99 | $126.42 $89.44 (29%) | 🛒 Add to cart |
| 120 | $0.94 | $168.56 $112.66 (33%) | 🛒 Add to cart |
| 180 | $0.89 | $252.84 $160.82 (36%) | 🛒 Add to cart |
| 270 | $0.86
Best per pill | $379.26 $232.20 (39%) | 🛒 Add to cart |
Synonyms | |||
Bystolic (nebivolol) is a third-generation beta-blocker medication specifically engineered for the management of hypertension. It represents a significant advancement in cardiovascular therapy by offering a dual mechanism of action: selective beta-1 adrenergic receptor blockade and nitric oxide-mediated vasodilation. This unique pharmacodynamic profile allows for effective blood pressure reduction while mitigating many of the undesirable side effects commonly associated with older beta-blockers. It is indicated for the treatment of high blood pressure and may be used in heart failure in certain patients, offering a modern approach to cardiovascular risk management under the guidance of a healthcare professional.
Features
- Active Pharmaceutical Ingredient: Nebivolol hydrochloride.
- Pharmacological Class: Beta-1 selective adrenergic receptor blocker with vasodilatory properties.
- Available Strengths: 2.5 mg, 5 mg, 10 mg, and 20 mg film-coated tablets.
- Mechanism of Action: Combines highly selective beta-1 receptor antagonism with endothelium-dependent vasodilation via L-arginine/nitric oxide pathway modulation.
- Bioavailability: Approximately 12% in fast metabolizers (majority of population) and 96% in poor metabolizers.
- Half-life: Averages 12-19 hours, supporting once-daily dosing.
- Primary Route of Elimination: Hepatic metabolism via cytochrome P450 2D6 (CYP2D6) with subsequent renal excretion of metabolites.
Benefits
- Effective Blood Pressure Reduction: Provides consistent 24-hour antihypertensive efficacy through its dual mechanism, helping patients achieve target blood pressure goals.
- Favorable Hemodynamic Profile: Reduces heart rate and cardiac output while decreasing peripheral vascular resistance, which is often elevated in hypertensive patients.
- Potentially Improved Tolerability: The vasodilatory action may contribute to a lower incidence of fatigue, cold extremities, and sexual dysfunction compared to conventional beta-blockers.
- Metabolic Neutrality: Clinical studies suggest minimal adverse effects on glucose metabolism and lipid profiles, making it suitable for hypertensive patients with metabolic syndrome or diabetes.
- Cardioprotective Potential: Beyond blood pressure control, may offer benefits for patients with left ventricular dysfunction and heart failure.
- Once-Daily Dosing: Enhances patient adherence to long-term antihypertensive therapy.
Common use
Bystolic is primarily prescribed for the treatment of hypertension, either as monotherapy or in combination with other antihypertensive agents. It is used to lower elevated blood pressure, thereby reducing the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. In some clinical contexts, it may also be used in the management of chronic heart failure (usually stable NYHA Class II or III heart failure with reduced ejection fraction) as part of a comprehensive treatment regimen, though this is a more specialized use that requires careful titration and monitoring by a cardiologist.
Dosage and direction
The dosage of Bystolic must be individualized based on patient response and tolerability. The recommended starting dose for hypertension is 5 mg once daily, with or without food. Dosage may be increased at 2-week intervals to a maximum recommended dose of 40 mg once daily. For most patients, the effective dose range is 5 mg to 20 mg daily. In patients with severe renal impairment (CrCl <30 mL/min) or moderate hepatic impairment (Child-Pugh Class B), the recommended initial dose is 2.5 mg once daily; uptitration should be performed cautiously. The tablet should be swallowed whole with a glass of water and should not be chewed or crushed. Dose adjustments may be necessary when co-administered with certain other medications (see Drug Interactions).
Precautions
- Abrupt Cessation: Beta-blocker therapy should not be discontinued abruptly, as this may precipitate a rebound phenomenon leading to severe angina, myocardial infarction, or ventricular arrhythmias. Dose reduction should be gradual over 1-2 weeks with close monitoring.
- Peripheral Vascular Disease: May aggravate symptoms of arterial insufficiency (e.g., Raynaud’s disease, claudication). Use with caution.
- Anesthesia/Surgery: The heart’s ability to respond to reflex stimuli is impaired by beta-blockers. The anesthesiologist must be informed that the patient is on Bystolic prior to any major surgery.
- Diabetes and Hypoglycemia: Beta-blockers may mask some cardinal signs of hypoglycemia (e.g., tachycardia, palpitations). They may also potentiate insulin-induced hypoglycemia.
- Thyrotoxicosis: Nebivolol may mask clinical signs of hyperthyroidism, such as tachycardia.
- Bronchospastic Disease: Although nebivolol is beta-1 selective, caution should be exercised in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. Doses greater than 10 mg should be avoided in these patients.
- Psoriasis: Beta-blockers have been reported to exacerbate psoriasis.
Contraindications
Bystolic is contraindicated in patients with:
- Severe bradycardia (very low heart rate)
- Heart block greater than first degree (in the absence of a functioning pacemaker)
- Cardiogenic shock
- Decompensated cardiac failure requiring IV inotropic therapy
- Severe hepatic impairment (Child-Pugh Class C)
- Hypersensitivity to nebivolol or any component of the formulation
- Sick sinus syndrome (unless a permanent pacemaker is in place)
Possible side effect
Like all medicines, Bystolic can cause side effects, although not everybody gets them. The most common side effects (≥1% and more common than placebo) include:
- Very Common (≥1/10): Headache.
- Common (≥1/100 to <1/10): Dizziness, fatigue, paresthesia (tingling/numbness), diarrhea, nausea, dyspnea (shortness of breath), bradycardia, rash, peripheral edema. Less common but more serious side effects require immediate medical attention:
- Uncommon (≥1/1,000 to <1/100): Heart block, worsening of heart failure, syncope (fainting), severe hypotension, depression, hallucinations, nightmares, erectile dysfunction, bronchospasm.
- Rare (≥1/10,000 to <1/1,000): Allergic reactions (angioedema, urticaria), psoriasis-like rash, visual disturbances.
Drug interaction
Bystolic has the potential to interact with several other medications. Key interactions include:
- Other Antihypertensives: Concomitant use with other blood pressure-lowering drugs (e.g., calcium channel blockers like diltiazem/verapamil, alpha-blockers, other beta-blockers) may potentiate hypotensive and bradycardic effects.
- CYP2D6 Inhibitors: Drugs that inhibit the cytochrome P450 2D6 enzyme (e.g., fluoxetine, paroxetine, quinidine, propafenone) can significantly increase nebivolol plasma levels, increasing the risk of adverse effects. Dose adjustment may be necessary.
- Antiarrhythmics: Concomitant use with Class I antiarrhythmic agents (e.g., disopyramide) may have additive negative inotropic effects and prolong atrial conduction time.
- Digoxin: Concomitant use may increase the risk of bradycardia.
- Clonidine: Concurrent use with beta-blockers may potentiate the rebound hypertension effect following clonidine withdrawal. Bystolic should be discontinued several days before the gradual withdrawal of clonidine.
- MAO Inhibitors: Concurrent use can exaggerate the hypotensive effect.
Missed dose
If a dose is missed, it should be taken as soon as possible on the same day. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. The patient should not take a double dose to make up for a forgotten one. Maintaining a consistent daily schedule is important for optimal blood pressure control.
Overdose
Overdose with Bystolic is primarily characterized by severe bradycardia, hypotension, heart failure, bronchospasm, and hypoglycemia. In case of suspected overdose, immediate medical attention is required. Treatment is primarily supportive and symptomatic. Based on the expected pharmacologic effects, the following may be considered under medical supervision:
- Bradycardia: Administer atropine intravenously. If the response is inadequate, isoproterenol (a beta-agonist) can be given cautiously. In refractory cases, transvenous cardiac pacing may be required.
- Hypotension: Administer IV fluids and vasopressors (e.g., epinephrine, dopamine, dobutamine). The choice of vasopressor should consider that nebivolol is a beta-blocker.
- Heart Failure: Administer diuretics and digitalis glycosides.
- Bronchospasm: Administer bronchodilators (e.g., beta2-agonists such as salbutamol).
- Hypoglycemia: Administer IV glucose. Gastric lavage may be considered if ingestion was recent.
Storage
Store Bystolic tablets at room temperature between 20°C to 25°C (68°F to 77°F). Excursions are permitted between 15°C and 30°C (59°F and 86°F). Keep the medication in its original blister package or bottle to protect it from light and moisture. Keep all medicines out of the sight and reach of children and pets. Do not use medicine after the expiration date printed on the packaging.
Disclaimer
This information is for educational and informational purposes only and does not constitute medical advice. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read here. The content provided is based on the drug’s prescribing information but may not be all-inclusive. Individual patient responses to medication can vary.
Reviews
- Clinical Consensus: Bystolic (nebivolol) is generally well-regarded in the cardiology community for its efficacy in hypertension and its favorable side effect profile compared to traditional beta-blockers. Its hemodynamic and metabolic benefits are frequently cited in clinical literature.
- Patient Feedback (Aggregated): Many patients report successful blood pressure control with Bystolic. Positive reviews often mention a lack of the fatigue and sexual side effects sometimes experienced with other beta-blockers. Some negative reviews cite initial side effects like dizziness or headache, which often subside after the titration period, or difficulties with the cost of the brand-name medication.
- Overall Efficacy: Consistently rated as effective for its primary indication of lowering blood pressure. Its role in heart failure is more specialized but supported by clinical trial data.